Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126045451 | 12604545 | 1 | I | 20160721 | 20160728 | 20160728 | EXP | IL-MYLANLABS-2016M1030840 | MYLAN | HAR-SHAI L, SAVIN Z, CANZONIERO JV. FULMINATING COURSE OF DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS EXACERBATED BY A STEVENS-JOHNSON SYNDROME/TOXIC EPIDERMAL NECROLYSIS OVERLAP. ISR-MED-ASSOC-J 2016;18(5):304-305. | 0.00 | Y | 0.00000 | 20160728 | OT | IL | IL |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126045451 | 12604545 | 1 | PS | VANCOMYCIN | VANCOMYCIN | 1 | Intravenous (not otherwise specified) | 65397 | INJECTION | ||||||||||
| 126045451 | 12604545 | 2 | SS | VANCOMYCIN | VANCOMYCIN | 1 | Unknown | 65397 | INJECTION | ||||||||||
| 126045451 | 12604545 | 3 | SS | LINEZOLID. | LINEZOLID | 1 | Unknown | 0 | |||||||||||
| 126045451 | 12604545 | 4 | SS | PIPERACILLIN/TAZOBACTAM | PIPERACILLIN SODIUMTAZOBACTAM SODIUM | 1 | Unknown | 0 | |||||||||||
| 126045451 | 12604545 | 5 | SS | DOXYCYCLINE. | DOXYCYCLINE | 1 | Unknown | 0 | |||||||||||
| 126045451 | 12604545 | 6 | SS | CIPROFLOXACIN. | CIPROFLOXACIN | 1 | Unknown | 0 | |||||||||||
| 126045451 | 12604545 | 7 | SS | CEFTAROLINE FOSAMIL | CEFTAROLINE FOSAMIL | 1 | Unknown | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126045451 | 12604545 | 1 | Sepsis |
| 126045451 | 12604545 | 3 | Staphylococcal infection |
| 126045451 | 12604545 | 4 | Sepsis |
| 126045451 | 12604545 | 5 | Sepsis |
| 126045451 | 12604545 | 6 | Product used for unknown indication |
| 126045451 | 12604545 | 7 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126045451 | 12604545 | HO |
| 126045451 | 12604545 | DE |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126045451 | 12604545 | Acute kidney injury | |
| 126045451 | 12604545 | Apnoea | |
| 126045451 | 12604545 | Cardiac failure | |
| 126045451 | 12604545 | Drug reaction with eosinophilia and systemic symptoms | |
| 126045451 | 12604545 | Hepatitis | |
| 126045451 | 12604545 | Septic shock | |
| 126045451 | 12604545 | Staphylococcal bacteraemia | |
| 126045451 | 12604545 | Stevens-Johnson syndrome | |
| 126045451 | 12604545 | Thyroiditis | |
| 126045451 | 12604545 | Toxic epidermal necrolysis | |
| 126045451 | 12604545 | Tubulointerstitial nephritis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |